Another great win for aspirin, especially considering the prevalence of NAFLD, NASH, fibrosis\/cirrhosis and even liver cancer. This post comes mere minutes after the post on a single tablet aspirin (300mg) daily putting a terminal liver cancer in remission. This study below used a low-dose (81mg) aspirin, but given the benefits of the “high-dose” (300mg) in the prior study I don’t see a reason not to try higher doses for even stronger effects in NAFLD\/NASH\/fibrosis cases.<\/p>\n
https:\/\/www.natap.org\/2023\/AASLD\/AASLD_100.htm<\/a><\/p>\n https:\/\/www.medscape.com\/viewarticle\/998550<\/a><\/p>\n “…Patients with metabolic-associated steatotic liver disease (MASLD, formerly NAFLD) without\u00a0cirrhosis<\/a>\u00a0who took daily low-dose\u00a0aspirin<\/a>\u00a0in a double-blind\u00a0randomized trial<\/a> demonstated significant reductions in liver fat content over 6 months compared with similar patients who took a placebo<\/strong><\/span>, study results show. “In MASLD without cirrhosis, low-dose aspirin, 81 milligrams daily, led to decreases in liver fat and improved markers of hepatic inflammation and fibrosis<\/strong><\/span>,” reported Robert M. Wilechansky, MD, a transplant hepatology fellow at Massachusetts General Hospital in Boston. “It was safe and well tolerated in this study<\/strong><\/span>, but we would like to see larger, longer-term clinical trials to test the efficacy of aspirin for improving histology and preventing adverse outcomes in MASLD,” he said here at The Liver Meeting 2023: American Association for the Study of Liver Diseases (AASLD).”<\/p>\n “…Aspirin was also associated with significantly greater reductions in liver transaminase levels and liver stiffness by VCTE<\/strong><\/span>. About one third of patients in each study arm had at least one adverse event. There was only one aspirin-related adverse event (heartburn) that led to discontinuation. There were no serious bleeding events in either arm<\/strong><\/span>. “We’re going to have to consider stratifying by aspirin use now in our trials,” said Mark Hartman, MD, from Eli Lilly & Co. in Indianapolis.”<\/p>\n","protected":false},"excerpt":{"rendered":" Another great win for aspirin, especially considering the prevalence of NAFLD, NASH, fibrosis\/cirrhosis and even liver cancer….<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[326,65,380,64,12,61,59,60],"class_list":["post-2457","post","type-post","status-publish","format-standard","hentry","category-science","tag-aspirin","tag-cirrhosis","tag-fat","tag-fibrosis","tag-inflammation","tag-liver","tag-nafld","tag-nash","wpcat-2-id"],"_links":{"self":[{"href":"https:\/\/haidut.me\/index.php?rest_route=\/wp\/v2\/posts\/2457","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haidut.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haidut.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haidut.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haidut.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2457"}],"version-history":[{"count":3,"href":"https:\/\/haidut.me\/index.php?rest_route=\/wp\/v2\/posts\/2457\/revisions"}],"predecessor-version":[{"id":2460,"href":"https:\/\/haidut.me\/index.php?rest_route=\/wp\/v2\/posts\/2457\/revisions\/2460"}],"wp:attachment":[{"href":"https:\/\/haidut.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2457"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haidut.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2457"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haidut.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2457"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}